How have MDNA shares performed in 2024?

Medicenna Therapeutics' stock was trading at C$0.42 at the beginning of the year. Since then, MDNA shares have increased by 345.2% and is now trading at C$1.87. View the best growth stocks for 2024 here .

When is Medicenna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024. View our MDNA earnings forecast .

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK) , AbbVie (ABBV) , Livongo Health (LVGO) , Aptose Biosciences (APTO) , Birchcliff Energy (BIR) , CVS Health (CVS) , Freehold Royalties (FRU) , Fastly (FSLY) and Inovio Pharmaceuticals (INO) .

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Free MDNA Stock Alerts

C$1.84

-0.05 (-2.65%)

(As of 05:13 PM ET)

Compare

Today's Range: C$1.83
▼
C$1.95
50-Day Range: C$0.45
▼
C$1.96
52-Week Range: C$0.22
▼
C$2.10

Volume: 116,805 shs
Average Volume: 124,857 shs
Market Capitalization: C$128.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Headlines Insider Trades

Get Medicenna Therapeutics alerts:

Ad Wall Street Star

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

About Medicenna Therapeutics Stock (TSE:MDNA)

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

MDNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDNA Stock News Headlines

April 12, 2024 | americanbankingnews.com

Medicenna Therapeutics (TSE:MDNA) Trading Up 13.3%

April 9, 2024 | finance.yahoo.com

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

April 16, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 9, 2024 | finance.yahoo.com

Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

March 27, 2024 | theglobeandmail.com

Medicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)

March 6, 2024 | finance.yahoo.com

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

February 13, 2024 | finance.yahoo.com

Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

January 9, 2024 | finanznachrichten.de

Medicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

April 16, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

January 9, 2024 | finance.yahoo.com

Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

November 20, 2023 | finance.yahoo.com

All You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to Buy

November 14, 2023 | finanznachrichten.de

Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

November 9, 2023 | finance.yahoo.com

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

October 24, 2023 | tmcnet.com

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)

October 24, 2023 | finance.yahoo.com

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)

October 10, 2023 | finanznachrichten.de

Medicenna Therapeutics Corp.: Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

October 5, 2023 | nasdaq.com

Medicenna Therapeutics (MDNA) Price Target Increased by 34.63% to 3.93

October 3, 2023 | finance.yahoo.com

Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

September 29, 2023 | finanznachrichten.de

Medicenna Therapeutics Corp.: Medicenna Announces Results of Annual and Special Meeting of Shareholders

September 28, 2023 | finance.yahoo.com

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

September 26, 2023 | finance.yahoo.com

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?

September 6, 2023 | finance.yahoo.com

Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference

August 28, 2023 | msn.com

Medicenna Therapeutics gets new CFO

August 28, 2023 | finance.yahoo.com

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

August 24, 2023 | theglobeandmail.com

Closing Bell: Medicenna Therapeutics Corp up on Wednesday (MDNA)

August 13, 2023 | markets.businessinsider.com

Bloom Burton Thinks Medicenna Therapeutics Corp’s Stock is Going to Recover

August 9, 2023 | finance.yahoo.com

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

See More Headlines

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/16/2024
Next Earnings (Estimated): 6/25/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: TSE:MDNA
CUSIP: N/A
CIK: N/A
Web: www.medicenna.com
Phone: +1-403-6807898
Fax: N/A
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C($0.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-15,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -59.47%
Return on Assets: -34.57%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 5.00
Quick Ratio: 4.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$1.66 per share
Price / Cash Flow: 1.15
Book Value: C$0.27 per share
Price / Book: 7.04

Miscellaneous

Outstanding Shares: 69,640,000
Free Float: N/A
Market Cap: C$132.32 million
Optionable: Not Optionable
Beta: 1.16

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Fahar Merchant Ph.D. (Age 67)
Founder, Chairman, President & CEO
Comp: $454.37k
Ms. Rosemina Merchant B.Sc. (Age 67)
M.E.Sc, Founder & Chief Development Officer
Comp: $364.46k
Dr. Humphrey A. R. Gardner FCAP
M.D., Chief Medical Officer
Dr. Samuel R. Denmeade M.D.
Scientific Advisor

Key Competitors

View All Competitors

MDNA Stock Analysis - Frequently Asked Questions

How have MDNA shares performed in 2024?: Medicenna Therapeutics' stock was trading at C$0.42 at the beginning of the year. Since then, MDNA shares have increased by 345.2% and is now trading at C$1.87.
View the best growth stocks for 2024 here.
When is Medicenna Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024.
View our MDNA earnings forecast.
What other stocks do shareholders of Medicenna Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).
How do I buy shares of Medicenna Therapeutics?: Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:MDNA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial